Takeda Pharmaceuticals is in talks over the purchase of Switzerland-based pharmaceutical firm Nycomed, currently controlled by Nordic Capital and a private-equity unit of Credit Suisse.
Takeda is believed to be seeking acquisitions to alleviate projected earning declines associated with increased generic competition to its blockbuster diabetes medication, Actos.
According to Bloomberg, the deal is said to be tentative and is expected to broaden Takeda’s presence in emerging markets.
Any acquisition of Nycomed would provide Takeda with access to heartburn drug pantoprazole and cough medication roflumilast, both of which contributed to Nycomed’s 2010 earnings before interest, tax, deprecation and amortisation of €774.9m ($1.09bn).
Nycomed has been benefiting from an increasing presence in emerging markets, with 39% of its sales revenue originating from these markets, and the company had previously announced intentions to raise this figure to 60%.